Sandip Kapadia Sells 1,775 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 1,775 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sandip Kapadia also recently made the following trade(s):

• On Tuesday, January 21st, Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00.

Harmony Biosciences Trading Up 0.4 %

HRMY stock traded up $0.17 during mid-day trading on Tuesday, reaching $38.42. The company’s stock had a trading volume of 519,661 shares, compared to its average volume of 579,787. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The business’s 50 day moving average price is $34.86 and its 200 day moving average price is $35.12. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 18.21, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. On average, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on HRMY. Cantor Fitzgerald raised their price target on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Mizuho raised their target price on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Raymond James reiterated an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research note on Monday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $55.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. raised its position in shares of Harmony Biosciences by 19.8% during the second quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company’s stock worth $1,852,000 after purchasing an additional 10,167 shares during the period. Dimensional Fund Advisors LP raised its holdings in Harmony Biosciences by 13.3% during the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after buying an additional 112,197 shares during the last quarter. Hsbc Holdings PLC lifted its stake in shares of Harmony Biosciences by 208.1% in the second quarter. Hsbc Holdings PLC now owns 23,800 shares of the company’s stock valued at $731,000 after buying an additional 16,076 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Harmony Biosciences by 2.9% during the second quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock valued at $2,113,000 after buying an additional 1,955 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in shares of Harmony Biosciences by 145.4% in the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after acquiring an additional 181,092 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.